Regeneron Pharmaceuticals, Inc. Furnishes and Full Year 2025 Financial Results
Summary
Regeneron Pharmaceuticals, Inc. furnished its financial and operating results for the fourth quarter and full year ended December 31, 2025, via a press release (Ex. 99.1) on January 30, 2026. The company reported fourth quarter 2025 revenues increased 3% to $3.9 billion and full year 2025 revenues increased 1% to $14.3 billion. Dupixent® global net sales saw significant growth, while total EYLEA HD® and EYLEA® U.S. net sales decreased. * GAAP EPS was $7.86, with non-GAAP EPS of $11.44. * Dupixent® global net sales increased 34% to $4.9 billion in . * EYLEA HD® U.S. net sales increased 66% to $506 million in . * FDA approved EYLEA HD® for macular edema following retinal vein occlusion and for monthly dosing flexibility.
Why It Matters
Investors should note the reported Q4 2025 revenue growth of 3% to $3.9 billion and the significant 34% increase in Dupixent® global net sales to $4.9 billion. Additionally, FDA approvals for EYLEA HD® for new indications and dosing flexibility could impact future product performance and market share.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“Press Release, dated January 30, 2026, Reporting Fourth Quarter and Full Year 2025 Financial and Operating Results. (exhibit991q42025.htm).”
— From Item 9.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Friday, January 30, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive